NCT05926518View on ClinicalTrials.gov

Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients

CompletedOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

April 1, 2022

Study Completion Date

November 23, 2022

Conditions
Critical IllnessTherapeutic Drug MonitoringVenous Thromboembolism
Interventions
PROCEDURE

blood sampling

Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.

Trial Locations (1)

6815 AD

Monique de Maat, Arnhem

All Listed Sponsors
lead

Rijnstate Hospital

OTHER

NCT05926518 - Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients | Biotech Hunter | Biotech Hunter